Neha Atale

Dr. Neha Atale

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
NANeha Atale
Neha Atale
CMChandra Mishra
Chandra Mishra
SKShrey Kohli
Shrey Kohli
RMRAJ MONGRE
RAJ MONGRE
APAmresh Prakash
Amresh Prakash
VRVibha Rani
Vibha Rani
Black berry (Syzygium cumini) fruit is useful in curing diabetic complications; however, its role in diabetes‐induced cardiomyopathy is not yet known. In this study, we investigated the regulation of gelatinase‐B (MMP‐9) by S. cumini methanol seed extract (MSE) in diabetic cardiomyopathy using real‐time PCR, RT‐PCR, immunocytochemistry, gel diffusion assay, and substrate zymography. The regulatory effects of MSE on NF‐κB, TNF‐α, and IL‐6 were also examined. Identification and estimation of polyphenol constituents present in S. cumini extract were carried out using reverse‐phase HPLC. Further, in silico docking studies of identified polyphenols with gelatinase‐B were performed to elucidate molecular level interaction in the active site of gelatinase‐B. Docking studies showed strong interaction of S. cumini polyphenols with gelatinase‐B. Our findings indicate that MSE significantly suppresses gelatinase‐B expression and activity in high‐glucose‐ (HG‐) stimulated cardiomyopathy. Further, HG‐induced activation of NF‐κB, TNF‐α, and IL‐6 was also remarkably reduced by MSE. Our results suggest that S. cumini MSE may be useful as an effective functional food and dietary supplement to regulate HG‐induced cardiac stress through gelatinase.

Verified
Journal Article
Open access
PDF file
NANeha Atale
Neha Atale
Alan WellsAlan Wells
Alan Wells
Metastasis is a leading cause of mortality in breast cancer, as metastatic disease is often aggressive and resistant to conventional treatments. Cancer cells that spread to distant organs can enter a dormant phase for extended periods, sometimes years or decades. During this dormant phase, cancer cells avoid immune and pharmacological response. Thus, new approaches are needed to prevent these disseminated cells from becoming lethal cancers. Statins are known inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that have been extensively used in patients with cardiovascular diseases to lower cholesterol. However, recent research has demonstrated their potential in anticancer therapies. Epidemiological evidence suggests that statins are associated with a reduction in breast cancer-specific mortality, although they do not appear to affect the incidence of primary tumors. In this review, we discuss the role of statins in metastasis and dormancy, their cytocidal and cytostatic effects and their interactions with different cell types in the tumor microenvironment. The exact mechanisms by which statins reduce mortality without influencing primary tumor growth remain unclear, also warranting further investigation into their potential role in metastasis and tumor dormancy, which could ultimately help patients to improve survival and quality of life.

19 November 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
VRVibha Rani
Vibha Rani
Dhananjay YadavDhananjay Yadav
Dhananjay Yadav
NANeha Atale
Neha Atale
Background: Cancer is a wide range cellular level disease that occurs when cells go through uncontrolled division and growth. The mechanisms by which the cells undergo metastasis are complex and involve many interactions between the tumor cells and their cellular environment. Matrix metalloproteinases (MMPs) have been found to over-express at various stages of tumor progression and their inhibition using MMP inhibitors has been a subject of potential therapy against cancer. Objective: This review discusses recent research in MMP inhibitors (MMPI) used for preventing tumor progression. Methods: In this review, we explored the role of MMPs in cancer progression and summarized the current developments in MMPIs, their role in cancer suppression in in vitro and in vivo studies and their evaluation in clinical trials from the current research data. Results: MMPIs have shown to be very successful in in vitro models, cell lines and in some in vivo studies. Unfortunately, their efficacy in clinical trials has been found to be hit and miss. Recent studies have shown that the novel delivery approaches of MMP inhibitors may enhance their therapeutic effects towards the prevention of cancer. Conclusion: In this review, we presented different MMP inhibitors, their performance at different stages of models - in vitro, in vivo, small animal models and eventually clinical trials. We provide newer methods of MMPI delivery that may be better targeted to suppress only specific MMPs and avoid toxic side effects in healthy cells.

2 November 2025 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
NANeha Atale
Neha Atale
ZLZihan Ling
Zihan Ling
XRXi Ren
Xi Ren
KNKentaro Noda
Kentaro Noda
Pablo G. G SanchezPablo G. G Sanchez
Pablo G. G Sanchez
Background: Developing clinically relevant experimental models of the human airway can significantly advance our understanding of the mechanisms underlying airway diseases and aid in translating potential therapies to clinical settings. The aim of this study is to establish an ex vivo human airway tissue culture model. Methods: Human donor airway tissues were obtained from clinical cases of lung transplantation. Our established method is based on the concept of scavenging metabolic activity and controlling bacterial growth and includes increased media volume, frequent media exchange, and antifungal additives to efficiently maintain the homeostatic culture environment. After a 3-day culture period, the airway was investigated, and its viability and function were compared with a standard cell culture method. Results: Control tissue exhibited significant acidosis after 3 days, suggesting high metabolic activity of airway tissue and bacterial contamination. The airway epithelial viability—after culturing in our established method for 3 days—was better than that of the controls. We only performed an acute but early investigation of the cultures as airway complications have been known to start early at the proximal bronchus after transplantation. H&E and alcian blue staining showed intact morphology of the epithelium of airway tissue and mucus layers after 3 days in our model, while controls showed remarkable damage to the epithelial layer. Newly synthesized glycoproteins were detected in the epithelial layer using metabolic labeling and the click chemistry technique, suggesting cellular protein synthesis of the airway tissue in our established ex vivo model. Conclusions: We successfully established a reproducible model of human ex vivo airway tissue culture (n = 3 independent biological samples) that may be useful for investigating airway complications and developing their therapies.

26 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Bei DaiBei Dai
Bei Dai
NANeha Atale
Neha Atale
Amanda M ClarkAmanda M Clark
Amanda M Clark
Alan WellsAlan Wells
Alan Wells
The major event that leads to death from breast cancer (BrCa) is the emergence of micrometastases into lethal growing metastases. While it is still uncertain what regulates the cell fate decision between remaining in dormancy and aggressive proliferative progression, accumulating evidence demonstrates a major role for the metastatic microenvironment. One area of interest is that of tissue and circulating mesenchymal stem cells (MSCs), which have been shown to alter the proliferative and metastatic potential of BrCa. Herein, we investigate how these cells impact the phenotype of metastatic BrCa. As the disseminated BrCa cells initially adopt an epithelial phenotype in ectopic organs, one that is dormant in having limited proliferation and being immune-silent, interactions that revert the disseminated metastatic BrCa to aggressive mesenchymal phenotypes, would be a driver of metastatic progression. BrCa cells exhibited phenotypic changes including increased E-cadherin expression, altered proliferation, and differential sensitivity to TRAIL-induced apoptosis when directly co-cultured with immortalized human MSCs, compared to the BrCa cells not co-cultured. These regulatory effects were dependent upon the BrCa cell’s epithelial–mesenchymal status and involved distinct juxtacrine and paracrine signaling mechanisms, as evidenced by differing responses in direct co-culture, conditioned medium, and Transwell systems. Our findings highlight the complex and context-dependent roles of MSCs in BrCa progression, improving our understanding of tumor-stroma interactions and laying groundwork for future therapeutic exploration.

26 September 2026 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
NANeha Atale
Neha Atale
VRVibha Rani
Vibha Rani
Despite substantial progress in immunotherapies and targeted therapies, alongside conventional modalities such as surgery, radiotherapy, and chemotherapy, cancer treatment continues to pose significant challenges. Natural products are central to advancing innovative anticancer agents in oncological research, enabling the scientific community to explore novel compounds derived from nature for combating malignancies. Notably, several agents like vincristine and quercetin have been demonstrated to have substantial efficacy in managing leukemia and breast cancer, etc. Computational approaches represent a foundational strategy in drug discovery among diverse methodologies. This review reveals the role of natural products as prospective anticancer agents and delineates structure- based drug discovery methods and their contributions to rationalizing therapeutic development. This also highlights the deployment of natural products in cancer therapeutics, prevailing computational strategies leveraging these compounds for drug design, and their critical role in the discovery continuum. Ultimately, natural products combined with established computational drug discovery frameworks offer considerable potential in the management of cancer treatment.